What if we could
cure fatal rare
disease?


Rare Monogenic Disease
Many rare diseases are caused by a single mutation in a gene, which leads to a build up of a misfolded, non-functional protein. These proteins go on to do serious damage to the cell and therefore cause often significant disease. And very often they inhibit the ability of the cell to undergo autophagy which itself leads to more damage.
So if we boost autophagy we can remove the misfolded, cytotoxic protein, restore the cell’s ability to undergo autophagy, and in some cases we find that we can also restore the function of the mutated protein. This means restoring autophagy is not just helping an aspect of the disease but is truly curative.
In Samsara we are studying specific rare genetic peripheral nervous system and liver diseases where we believe autophagy can be completely curative.
This could be life-changing for many patients suffering with severe diseases which are currently poorly treated.
Samsara Therapeutics Establishes Scientific Advisory Board
Michael Schlossmacher, Susan Perlman, Ed Tate and Christian Behl to help advance development of neurodegeneration and rare genetic disease therapeutics
More additions to the Samsara Therapeutics team
We’re pleased to report that we’ve further strengthened our team in Oxford.
Neurodegeneration, lysosomal dysfunction and autophagy
There is a desperate need for novel therapies that can prevent the progressive neurodegeneration in debilitating diseases of ageing, such as Alzheimer’s, Parkinson’s and Huntington’s Disease.
New home and strengthening our scientific team
It’s a busy time for Samsara Therapeutics as we move into our new purpose-built labs and offices in the Wood Centre for Innovation in Oxford.
© 2021 Samsara Therapeutics | Legal Information | Privacy
© 2021 Samsara Therapeutics
Legal Information | Privacy